<br>促进抗原特异性免疫耐受的组织靶向药物递送策略,Advanced Healthcare Materials

当前位置： X-MOL 学术 › Adv. Healthcare Mater. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

促进抗原特异性免疫耐受的组织靶向药物递送策略
Advanced Healthcare Materials ( IF 10.0 ) Pub Date : 2022-11-23 , DOI: 10.1002/adhm.202202238
Yuan Rui ₁ , Haleigh B Eppler _{1,

2} , Alexis A Yanes ₁ , Christopher M Jewell _{1,

2,

3,

4,

5,

6}

Affiliation

在自身免疫或器官移植排斥反应期间，免疫系统会攻击宿主或移植组织，导致数百万患者出现使人衰弱的炎症。大多数这些疾病无法治愈。此外，可用的疗法通过非特异性途径调节炎症，减轻症状，但也损害了患者产生健康免疫反应的能力。最近通过疫苗样抗原特异性调节免疫功能障碍的临床前进展揭示了解决自身免疫性疾病和移植排斥反应的根本原因的令人兴奋的机会。其中一些疗法目前正在进行临床试验，这突显了抗原特异性耐受性的前景。实现抗原特异性耐受性需要抗原、细胞因子、小分子药物和其他免疫调节剂的精确且通常的组合递送。这可以通过生物材料技术来实现，生物材料技术可以被设计为定向和显示免疫线索，防止降解，并选择性地将信号传递给特定组织或细胞群。在本综述中，描述了一些参与自身免疫和健康免疫耐受的关键免疫细胞群。讨论了将药物递送到免疫器官的机会，其中专门的组织驻留免疫细胞可以被编程以独特的方式对抗原做出反应。最后，重点介绍了目前正在进行临床试验的基于细胞和生物材料的诱导抗原特异性免疫耐受的疗法。

"点击查看英文标题和摘要"

Tissue-Targeted Drug Delivery Strategies to Promote Antigen-Specific Immune Tolerance

During autoimmunity or organ transplant rejection, the immune system attacks host or transplanted tissue, causing debilitating inflammation for millions of patients. There is no cure for most of these diseases. Further, available therapies modulate inflammation through nonspecific pathways, reducing symptoms but also compromising patients’ ability to mount healthy immune responses. Recent preclinical advances to regulate immune dysfunction with vaccine-like antigen specificity reveal exciting opportunities to address the root cause of autoimmune diseases and transplant rejection. Several of these therapies are currently undergoing clinical trials, underscoring the promise of antigen-specific tolerance. Achieving antigen-specific tolerance requires precision and often combinatorial delivery of antigen, cytokines, small molecule drugs, and other immunomodulators. This can be facilitated by biomaterial technologies, which can be engineered to orient and display immunological cues, protect against degradation, and selectively deliver signals to specific tissues or cell populations. In this review, some key immune cell populations involved in autoimmunity and healthy immune tolerance are described. Opportunities for drug delivery to immunological organs are discussed, where specialized tissue-resident immune cells can be programmed to respond in unique ways toward antigen. Finally, cell- and biomaterial-based therapies to induce antigen-specific immune tolerance that are currently undergoing clinical trials are highlighted.

更新日期：2022-11-23

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南